Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA

• Published in: Biochemical pharmacology Vol. 70; no. 12; pp. 1717 - 1725
• Main Authors: Meczes, Emma L., Azim-Araghi, Ali, Ottley, Christopher J., Pearson, D. Graham, Tilby, Michael J.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 05.12.2005; Elsevier Science
• Subjects: Antibodies, Monoclonal - immunology; Antineoplastic agents; Biological and medical sciences; Chromatography, Ion Exchange; Cisplatin; Cisplatin - metabolism; DNA adduct; DNA Adducts - analysis; DNA Adducts - immunology; Enzyme-Linked Immunosorbent Assay; General aspects; Humans; ICP-MS; Immunoassay; Ion-exchange chromatography; Medical sciences; Oligodeoxyribonucleotides - immunology; Oligonucleotide; Pharmacology. Drug treatments; DNA adduct; Immunoassay; Oligonucleotide; ICP-MS; Ion-exchange chromatography; Cisplatin; Antineoplastic agent; Monoclonal antibody; Inductive coupling plasma spectrometry; Ion exchange chromatography; Immunological method; Alkylating agent; Analysis method; DNA; Mechanism of action; Molecular adduct; Platinum II Complexes

Numerous clinical or experimental studies have employed monoclonal antibody CP9/19 for quantification of cisplatin DNA adducts. The nature of adducts recognised by CP9/19 on polymeric DNA were defined using synthetic deoxynucleotides reacted with cisplatin. Total adduct levels were determined by ato...